HALO insider transactions
Halozyme Therapeutics Inc. (HALO) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for HALO
- PRESIDENT AND CEO Torley Helen sold $3,370,008 worth of shares (50,000 units at $67.40) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $12.07 (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $107,591 worth of shares (1,625 units at $66.21) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 43,669 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 50,000 shares at a strike of $12.07 and sold $3,433,875 worth of shares (50,000 units at $68.68) as part of a pre-agreed trading plan (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Posard Matthew L. was granted 3,796 shares, increasing direct ownership by 5% to 77,835 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Krishnan Mahesh was granted 3,796 shares, increasing direct ownership by 36% to 14,462 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Lang James Paul was granted 3,796 shares, increasing direct ownership by 427% to 4,685 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Henderson Jeffrey William was granted 3,796 shares, increasing direct ownership by 12% to 36,572 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Duncan Barbara Gayle was granted 3,796 shares, increasing direct ownership by 19% to 23,715 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette was granted 6,796 shares, increasing direct ownership by 18% to 45,294 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $103,155 worth of shares (1,625 units at $63.48) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 38,498 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by Torley Helen4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by Ramsay David A4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by Torley Helen4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 3 filed by new insider Ramsay David A3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF OPERATING OFFICER Caudill Cortney exercised 21,546 shares at a strike of $33.51 and sold $1,955,160 worth of shares (28,857 units at $67.75), decreasing direct ownership by 51% to 7,055 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 50,000 shares at a strike of $12.07 and sold $3,476,157 worth of shares (50,000 units at $69.52) (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF OPERATING OFFICER Caudill Cortney converted options into 2,666 shares and covered exercise/tax liability with 1,037 shares, increasing direct ownership by 13% to 14,366 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF LEGAL OFFICER Snyder Mark Howard converted options into 12,343 shares and covered exercise/tax liability with 6,658 shares, increasing direct ownership by 14% to 47,610 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole converted options into 12,020 shares and covered exercise/tax liability with 6,484 shares, increasing direct ownership by 17% to 38,494 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen covered exercise/tax liability with 21,144 shares and converted options into 39,193 shares, increasing direct ownership by 2% to 767,780 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF LEGAL OFFICER Snyder Mark Howard converted options into 16,812 shares and covered exercise/tax liability with 9,068 shares, increasing direct ownership by 23% to 41,925 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole converted options into 23,773 shares and covered exercise/tax liability with 12,894 shares, increasing direct ownership by 49% to 32,958 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen converted options into 89,055 shares and covered exercise/tax liability with 48,043 shares, increasing direct ownership by 6% to 749,731 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by SVP, CHIEF OPERATING OFFICER Caudill Cortney4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by SVP, CHIEF LEGAL OFFICER Snyder Mark Howard4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by PRESIDENT AND CEO Torley Helen4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 50,000 shares at a strike of $12.07 and sold $3,853,503 worth of shares (50,000 units at $77.07) (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Lang James Paul was granted 889 units of Restricted Stock Units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $140,500 worth of shares (2,000 units at $70.25), decreasing direct ownership by 5% to 40,123 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF LEGAL OFFICER Snyder Mark Howard converted options into 7,611 shares and covered exercise/tax liability with 4,243 shares, increasing direct ownership by 11% to 34,181 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 3 filed by new insider Lang James Paul3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF OPERATING OFFICER Caudill Cortney converted options into 9,326 shares and sold $277,905 worth of shares (4,263 units at $65.19), increasing direct ownership by 66% to 12,737 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by PRESIDENT AND CEO Torley Helen4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $59,356 worth of shares (829 units at $71.60), decreasing direct ownership by 2% to 42,123 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by Halozyme Therapeutics Inc.4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen sold $4,167,930 worth of shares (60,000 units at $69.47) and exercised 60,000 shares at a strike of $8.11 (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $136,960 worth of shares (2,000 units at $68.48), decreasing direct ownership by 4% to 42,952 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SEC Form 4 filed by SVP, CHIEF OPERATING OFFICER Caudill Cortney4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- New insider Caudill Cortney claimed ownership of 7,674 shares (SEC Form 3)3 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $8.11 and sold $4,311,745 worth of shares (60,000 units at $71.86) (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $150,481 worth of shares (2,000 units at $75.24), decreasing direct ownership by 4% to 44,952 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole sold $173,584 worth of shares (2,227 units at $77.95), decreasing direct ownership by 9% to 22,079 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF FINANCIAL OFFICER Labrosse Nicole exercised 12,406 shares at a strike of $12.11 and sold $1,514,267 worth of shares (20,000 units at $75.71), decreasing direct ownership by 24% to 24,306 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen sold $4,444,626 worth of shares (60,000 units at $74.08) and exercised 60,000 shares at a strike of $8.11 (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette sold $294,736 worth of shares (4,000 units at $73.68), decreasing direct ownership by 8% to 46,952 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $8.11 and sold $3,817,389 worth of shares (60,000 units at $63.62) (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $8.11 and sold $3,387,517 worth of shares (60,000 units at $56.46) (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- PRESIDENT AND CEO Torley Helen exercised 60,000 shares at a strike of $8.11 and sold $3,185,280 worth of shares (60,000 units at $53.09) (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF LEGAL OFFICER Snyder Mark Howard covered exercise/tax liability with 2,711 shares and converted options into 5,035 shares, increasing direct ownership by 8% to 30,813 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Posard Matthew L. was granted 4,165 shares, increasing direct ownership by 6% to 74,039 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Miyashita Akiko Moni was granted 4,165 shares, increasing direct ownership by 20% to 24,937 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Krishnan Mahesh was granted 4,165 shares, increasing direct ownership by 64% to 10,666 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Henderson Jeffrey William was granted 4,165 shares, increasing direct ownership by 15% to 32,776 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Duncan Barbara Gayle was granted 4,165 shares, increasing direct ownership by 26% to 19,919 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Connaughton Bernadette was granted 4,165 shares, increasing direct ownership by 9% to 50,952 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Henderson Jeffrey William sold $271,467 worth of shares (4,497 units at $60.37), decreasing direct ownership by 14% to 28,611 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Henderson Jeffrey William sold $32,217 worth of shares (503 units at $64.05), decreasing direct ownership by 1% to 33,108 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- Director Henderson Jeffrey William sold $293,458 worth of shares (5,000 units at $58.69), decreasing direct ownership by 13% to 33,611 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)
- SVP, CHIEF TECHNICAL OFFICER Labarre Michael J. sold $1,260,681 worth of shares (21,697 units at $58.10), decreasing direct ownership by 11% to 173,756 units (SEC Form 4)4 - HALOZYME THERAPEUTICS, INC. (0001159036) (Issuer)